Gilead Science Will Supply Four Drugs in Almería for €2 Million

Gilead Science grows in Andalusia. The regional government has invested €2 million in the supply of four drugs for health centers in the province of Almería, according to the contracting portal of the autonomous community.

The contract with the biotech company proposes an execution period of 36 months, extendable for another 24 more. To the disbursement of €2 million, the budget is added in case of modifications, which stands at another €382,656, while if eventual distributions are required, €191,328 will be added. In the case of the extension, the value of this would be €1.2 million. Taking all the assumptions into account, the contract could amount to up to €3.7 million.

In the agreement, it has been agreed that the disbursement of the regional Executive will be made by annuities. The first would be €442,180 and would include the supply for the first year, in 2024 and 2025 the amount would amount to €663,270, while in the last year, the outlay would be €221,090.

Read more details about Gilead Science and find the latest financial news of the day with the Born2Invest mobile app.

Gilead Science ensures the distribution of these drugs for three years, extendable for another two years

The agreement grants exclusivity of supply to the biotech Gilead Science for drugs that include the following active ingredients: amphotericin, aztreonam, sacituzumab govitecan, and emtricitabine.

The contract is distributed in four lots. The first of these corresponds to amphotericin, which the company markets under the name Ambisome and which represents an outlay of 447,911 euros. It is an injectable drug used in the treatment of infections caused by fungi. The cost of each unit of this medication is 76.56 euros and 5,850 units are included in the agreement.  

The second batch is aztreonam, which the biotech company markets under the name Cayson. The amount of supply is this antibiotic, used in the treatment of chronic lung infections caused by the bacterium Pseudomonas aeruginosa, is €435,267 cost. The unit cost is €24.80 and the regional Executive has purchased up to 17,551 units of these solutions.

The drug for the treatment of metastatic breast cancer, Trodelvy, which responds to the generic sacituzumab govitecan, has involved the disbursement of €948,480 to the Andalusian Health Service (SAS). Each unit of this injectable drug has been estimated at €608 and the US company will distribute up to 1,560 units.   

The global data of Gilead Science reflect that it had a turnover of €6.4 billion in the first quarter of 2023

The latest batch is emtricitabine, which is marketed by Gilead Science as Emtriva and is used to treat human immunodeficiency virus . The distribution has been estimated at €81,623 for the supply of 3,900 drugs, with a unit value of each of them is €20.93.

Gilead Sciences had $6.4 billion in revenue in the first quarter of 2023, a 4% year-over-year decrease from the same period a year earlier. The company attributes the decline to declining sales of remdesivir, marketed under the name Veklury, which is a solution for the treatment of Covid-19. 

The biotech company founded in 1987 has 260 workers in the Spanish subsidiary, from which it markets 25 products. The group, headquartered in Foster City (California), has a presence in more than 35 countries around the world.

Among the latest investments by the Andalusian Executive, the construction project for a new health center in Alameda (Jaén) for €7.7 million stands out. The space will have a health center with an area of ​​2,900 square meters, as well as a mental health unit of 430 square meters. Both will provide health care to 11,500 people and have the will to “relieve health care in the area” according to the statement issued by the region.  

__

(Featured image by Val-gb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.